Canada· CA-DIN-02384884

TEVA-NABILONE

A nabilone product containing nabilone, registered in Canada by TEVA CANADA LIMITED. The same ATC class is registered in 4 of our 19 countries.

ATC A04AD11

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedTEVA-NABILONEATCA04AD11REGISTER NO.CA-DIN-02384884PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Nabilone is registered in 4 of 19 countries.

Countries holding a registration under ATC A04AD11 (nabilone), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 1 of them publish a price we can compare per daily dose

Nabilone · ATC A04AD11

4 / 19 countries

  • Canada
  • Germany
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
NABILONE
Manufacturer
TEVA CANADA LIMITED
Country
Canada (CA)
ATC code
A04AD11
ATC class
Nabilone
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

361 interactions on record for nabilone.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nabilone · interactions on record

361 records

  • 6 severe
  • 355 moderate

Most severe, free to view

  • Sodium oxybateN01AX11severe
  • DextropropoxypheneN02AC04severe
  • BuprenorphineN02AE01severe
  • MetoclopramideA03FA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nabilone in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nabilone products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Austria · Canemes
  • Germany · Canemes
  • United Kingdom (Northern Ireland) · Nabilone, Nabilone Brown & Burk Uk

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/afcab1c7-8742-4ea9-807f-e8297d013b38
GET /v1/drugs/afcab1c7-8742-4ea9-807f-e8297d013b38?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02384884",
  "form": "CAPSULE",
  "class": "Human",
  "routes": [
    "ORAL"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "A04AD11",
  "schedule": [
    "Narcotic (CDSA II)"
  ],
  "drug_code": "87056",
  "strengths": [
    "0.5 MG"
  ],
  "ahfs_class": null,
  "substances": [
    "NABILONE"
  ],
  "product_categorization": null
}

See everything about nabilone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.